100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R41AI142960
Award Date
12/15/18
Completion Date
2/14/21
Dollars Obligated
$738K
Overview
Activity
7
Transactions
7
Subawards
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Phagepro, P.b.c. (KHNEFNHKMN84)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Update #1
Update #2
DEVELOPING A SCALABLE MANUFACTURING PROCESS FOR AN ORAL BACTERIOPHAGE PRODUCT THAT PREVENTS CHOLERA
Posted 12/7/18
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
DEVELOPING A SCALABLE MANUFACTURING PROCESS FOR AN ORAL BACTERIOPHAGE PRODUCT THAT PREVENTS CHOLERA - PROJECT SUMMARY CHOLERA IS AN ACUTE AND SEVERE DISEASE CAUSED BY THE BACTERIUM VIBRIO CHOLERAE THAT IS SPREAD PRIMARILY THROUGH CONTAMINATED WATER SOURCES DUE TO A LACK OF ADEQUATE SANITATION INFRASTRUCTURE. THE WORLD HEALTH ORGANIZATION ESTIMATES THAT THERE ARE AT LEAST 3 MILLION CASES GLOBALLY PER YEAR, 40 PERCENT OF WHICH ARE SPREAD THROUGH HOUSEHOLD TRANSMISSION. CURRENT PREVENTION METHODS REQUIRE SIGNIFICANT INVESTMENT OF RESOURCES AND TIME FOR EFFICACY, BUT HOUSEHOLD CONTACTS OF CHOLERA PATIENTS OFTEN PRESENT WITH CHOLERA SYMPTOMS TWO TO THREE DAYS AFTER THE INITIAL PATIENT BECOMES SICK. IN ADDITION, THE PREVENTIVE USE OF ANTIBIOTICS IS NOT RECOMMENDED DUE TO WIDESPREAD RESISTANCE AND THE KNOWN NEGATIVE CONSEQUENCES OF DYSBIOSIS. THERE IS A PRESSING NEED TO DEVELOP A TARGETED CLINICAL INTERVENTION TO PREVENT THE COMMUNITY SPREAD OF CHOLERA USING A RAPID PROPHYLACTIC TREATMENT. THE GOAL OF THE PROPOSED STUDIES IS TO DEMONSTRATE FEASIBILITY OF DEVELOPING OUR PHAGE-BASED CLINICAL INTERVENTION, PROPHALYTIC-VC, TO PREVENT THE COMMUNITY SPREAD OF CHOLERA. PROPHALYTIC-VC IS AN ORALLY ADMINISTERED COCKTAIL OF THREE DIFFERENT PHAGES KNOWN AS ICP1, ICP2, AND ICP3. TO DATE, THESE ARE THE ONLY THREE VIRULENT PHAGES FOUND IN ASSOCIATION WITH EPIDEMIC STRAINS OF CHOLERA. DETAILED GENOMIC AND PHENOTYPIC CHARACTERIZATION EACH OF THE PHAGES HAS BEEN CONDUCTED BY THE ACADEMIC PARTNER, RESULTING IN GENOME SEQUENCES, ANNOTATION, AND IDENTIFICATION OF THE HOST RECEPTORS. THE COMBINATION OF THE THREE HAS BEEN EVALUATED TO DEMONSTRATE POTENCY IN REDUCING COLONIZATION OF V. CHOLERAE AND PREVENTION OF CHOLERA SYMPTOMS IN TWO ANIMAL MODELS OF V. CHOLERAE COLONIZATION AND PATHOGENESIS. HERE, WE PROPOSE STUDIES TO OPTIMIZE A ROBUST AND SCALABLE MANUFACTURING PROCESS FOR PROPHALYTIC-VC, AS THERE IS CURRENTLY LITTLE MANUFACTURING EXPERIENCE IN THE USA DUE TO THE NOVEL NATURE OF THE PRODUCT. WE WILL CONSTRUCT TWO PHAGE PRODUCTION STRAINS, DEVELOP A SCALABLE PHAGE PRODUCTION AND PURIFICATION SCHEME, AND EVALUATE ANY POTENTIAL LOCAL OF SYSTEMIC TOXICITY. AT THE SUCCESSFUL CONCLUSION OF PHASE I, WE WILL HAVE A RESULTANT MASTER PHAGE STOCK (MPS) OF PROPHALYTIC-VC FROM AN OPTIMIZED LARGE-SCALE PRODUCTION SCHEME THAT IS POTENT AGAINST V. CHOLERAE AND SAFE WITH REPEATED ORAL ADMINISTRATION. STTR PHASE II FUNDING WILL BE USED TO FUND FURTHER ACTIVITIES TO GENERATE A WORKING PHAGE SEED STOCK FROM THE MPS TO PROCEED WITH A PHASE I CLINICAL TRIAL.
$0
2/11/21
Not listed
DEVELOPING A SCALABLE MANUFACTURING PROCESS FOR AN ORAL BACTERIOPHAGE PRODUCT THAT PREVENTS CHOLERA - PROJECT SUMMARY CHOLERA IS AN ACUTE AND SEVERE DISEASE CAUSED BY THE BACTERIUM VIBRIO CHOLERAE THAT IS SPREAD PRIMARILY THROUGH CONTAMINATED WATER SOURCES DUE TO A LACK OF ADEQUATE SANITATION INFRASTRUCTURE. THE WORLD HEALTH ORGANIZATION ESTIMATES THAT THERE ARE AT LEAST 3 MILLION CASES GLOBALLY PER YEAR, 40 PERCENT OF WHICH ARE SPREAD THROUGH HOUSEHOLD TRANSMISSION. CURRENT PREVENTION METHODS REQUIRE SIGNIFICANT INVESTMENT OF RESOURCES AND TIME FOR EFFICACY, BUT HOUSEHOLD CONTACTS OF CHOLERA PATIENTS OFTEN PRESENT WITH CHOLERA SYMPTOMS TWO TO THREE DAYS AFTER THE INITIAL PATIENT BECOMES SICK. IN ADDITION, THE PREVENTIVE USE OF ANTIBIOTICS IS NOT RECOMMENDED DUE TO WIDESPREAD RESISTANCE AND THE KNOWN NEGATIVE CONSEQUENCES OF DYSBIOSIS. THERE IS A PRESSING NEED TO DEVELOP A TARGETED CLINICAL INTERVENTION TO PREVENT THE COMMUNITY SPREAD OF CHOLERA USING A RAPID PROPHYLACTIC TREATMENT. THE GOAL OF THE PROPOSED STUDIES IS TO DEMONSTRATE FEASIBILITY OF DEVELOPING OUR PHAGE-BASED CLINICAL INTERVENTION, PROPHALYTIC-VC, TO PREVENT THE COMMUNITY SPREAD OF CHOLERA. PROPHALYTIC-VC IS AN ORALLY ADMINISTERED COCKTAIL OF THREE DIFFERENT PHAGES KNOWN AS ICP1, ICP2, AND ICP3. TO DATE, THESE ARE THE ONLY THREE VIRULENT PHAGES FOUND IN ASSOCIATION WITH EPIDEMIC STRAINS OF CHOLERA. DETAILED GENOMIC AND PHENOTYPIC CHARACTERIZATION EACH OF THE PHAGES HAS BEEN CONDUCTED BY THE ACADEMIC PARTNER, RESULTING IN GENOME SEQUENCES, ANNOTATION, AND IDENTIFICATION OF THE HOST RECEPTORS. THE COMBINATION OF THE THREE HAS BEEN EVALUATED TO DEMONSTRATE POTENCY IN REDUCING COLONIZATION OF V. CHOLERAE AND PREVENTION OF CHOLERA SYMPTOMS IN TWO ANIMAL MODELS OF V. CHOLERAE COLONIZATION AND PATHOGENESIS. HERE, WE PROPOSE STUDIES TO OPTIMIZE A ROBUST AND SCALABLE MANUFACTURING PROCESS FOR PROPHALYTIC-VC, AS THERE IS CURRENTLY LITTLE MANUFACTURING EXPERIENCE IN THE USA DUE TO THE NOVEL NATURE OF THE PRODUCT. WE WILL CONSTRUCT TWO PHAGE PRODUCTION STRAINS, DEVELOP A SCALABLE PHAGE PRODUCTION AND PURIFICATION SCHEME, AND EVALUATE ANY POTENTIAL LOCAL OF SYSTEMIC TOXICITY. AT THE SUCCESSFUL CONCLUSION OF PHASE I, WE WILL HAVE A RESULTANT MASTER PHAGE STOCK (MPS) OF PROPHALYTIC-VC FROM AN OPTIMIZED LARGE-SCALE PRODUCTION SCHEME THAT IS POTENT AGAINST V. CHOLERAE AND SAFE WITH REPEATED ORAL ADMINISTRATION. STTR PHASE II FUNDING WILL BE USED TO FUND FURTHER ACTIVITIES TO GENERATE A WORKING PHAGE SEED STOCK FROM THE MPS TO PROCEED WITH A PHASE I CLINICAL TRIAL.
$0
2/11/21
Not listed
DEVELOPING A SCALABLE MANUFACTURING PROCESS FOR AN ORAL BACTERIOPHAGE PRODUCT THAT PREVENTS CHOLERA
$0
3/20/20
Not listed
DEVELOPING A SCALABLE MANUFACTURING PROCESS FOR AN ORAL BACTERIOPHAGE PRODUCT THAT PREVENTS CHOLERA
$83.0k
3/17/20
Not listed
DEVELOPING A SCALABLE MANUFACTURING PROCESS FOR AN ORAL BACTERIOPHAGE PRODUCT THAT PREVENTS CHOLERA
$55.0k
2/5/20